Moreover, mutant IL18 engineered for resistance to inhibitory binding of the high-affinity IL-18 decoy receptor also promoted the activity of NK cells, resulting in the enhancement of anti-tumor effects in mouse tumor models [29]. The gene discussed is IL18; the disease is neoplasm.